Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)

Corresponding author: So Hun Kim https://orcid.org/0000-0002-2554-3664 Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University College of Medicine, 27 Inhang-ro, Jung-gu, Incheon 22332, Korea E-mail: shoney@inha.ac. kr We appreciate your interest in and comments on our article entitled “Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease” that was published in Diabetes & Metabolism Journal [1]. You pointed out the limitations of using non-invasive biomarker models to diagnose advanced fibrosis. You also mentioned potential renal protective effects of specific anti-diabetic medications, such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonist (GLP-1RA), as well as lifestyle patterns. As mentioned in our manuscript, we did not perform a liver biopsy to diagnosis nonalcoholic fatty liver disease (NAFLD) or advanced fibrosis. Instead, we used validated non-invasive biomarker models such as fibrosis-4 (FIB-4) or the NAFLD fibrosis score (NFS), as well as abdominal ultrasonography for large-scale screening [2,3]. Most published studies have also used these methods, therefore, our results are comparable to previously published studies. Moreover, the 5.4% prevalence rate of ≥F3 (advanced fibrosis) in individuals with DM in this study is in agreement with reports using liver biopsy (~5%) [4,5] or magnetic resonance elastography (7%) [6]. We agree that a causal association between advanced liver fibrosis and incident chronic kidney disease (CKD) cannot be confirmed due to the observational design of this study. However, data from a clinical trial involving 261 patients with NAFLD showed that improvement in liver histology due to lifestyle modifications such as weight loss were linked with significantly improved renal outcomes [7], strongly suggesting the causal relationship between severity of NAFLD and CKD. Moreover, in a recent Chinese prospective trial in elderly type 2 diabetes mellitus (T2DM) patients, where they assessed advanced liver fibrosis with FIB-4 and NFS, there was a significant association between NAFLD fibrosis and CKD occurrence and progression, of which results were comparable to our study [8]. As for the potential renal protective effect of specific anti-diabetic medications, such as SGLT2i or GLP-1RA, this study enrolled patients from January 2000 to December 2016, when the annual prescription rate of both SGLT2 inhibitors and GLP-1 agonists were rather low [9] and neither SGLT2i nor GLP-1RA were prescribed to our study participants. As far as the differences in baseline covariates between the subgroups, it would have been nice if we used a propensity score matching (PSM) to balance data to approximate complete randomization, however given the small sample size in the NAFLD without fibrosis group, PSM may leave too few cases for meaningful analysis. In regard to lifestyle patterns, we have excluded those with significant alcohol consumption. Moreover, when we adjusted for current smoking and regular exercise (3 times/ week), the results remained similar to Table 4, although the Response